贝伐珠单抗联合厄洛替尼对晚期非小细胞肺癌患者疗效、血清CYFRA21-1水平及KPS评分的影响

目的观察贝伐珠单抗联合厄洛替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效及其对晚期NSCLC患者血清细胞角蛋白19片段抗原21-1(CYFRA21-1)水平、卡氏生存质量(KPS)评分及不良反应的影响。方法前瞻性选取2018年1月至2019年12月宣城市人民医院收治的80例晚期NSCLC患者,随机数字表法分为观察组及对照组,每组各40例。对照组给予口服厄洛替尼治疗,观察组给予贝伐珠单抗联合厄洛替尼治疗。3个疗程后进行疗效评价,并比较2组患者治疗前后血清CYFRA21-1水平、KPS评分变化情况。同时观察记录治疗期间患者不良反应的发生情况。结果治疗3个疗程后,观察组的总有效率82.50%,显著高于对照组的70.00%,差异有统计学意义(P<0.05)。治疗3个疗程后,观察组血清CYFRA21-1水平为(2.45±1.02)μg/L,显著低于治疗前的(6.24±2.01)μg/L,对照组血清CYFRA21-1水平为(3.37±1.13)μg/L,显著低于治疗前的(6.32±2.03)μg/L,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗3个疗程后,观察组KPS评分为(79.46±10.26)分,显著高于治疗前的(60.46±10.17)分,对照组KPS评分为(72.31±10.19)分,显著高于治疗前的(60.71±10.20)分,且观察组高于对照组,差异均有统计学意义(P<0.05)。观察组皮疹、腹泻、出血发病率分别为42.50%、17.50%、10.00%,均显著低于对照组的72.50%、40.00%、30.00%,差异均有统计学意义(P<0.05)。结论贝伐珠单抗联合厄洛替尼对晚期NSCLC疗效显著,可明显降低血清CYFRA21-1水平,减少不良反应的发生,提高晚期NSCLC患者的生存质量,具有一定临床应用价值。

Influences of bevacizumab combined with erlotinib on the efficacy,serum CYFRA21-1 level and KPS score of advanced NSCLC patients

Objective To observe the clinical efficacy of bevacizumab combined with erlotinib in the treatment of advanced non-small cell lung cancer(NSCLC)and its influences on the level of serum cytokeratin 19 fragment antigen 21-1(CYFRA21-1),Karnofsky Performance Scale(KPS)score and side effects.Methods From January 2018 to December 2019,80 patients with advanced NSCLC admitted to Xuancheng People's Hospital were prospectively selected and divided into observation group and control group by random number table,each group 40 cases.The control group was treated with oral erlotinib,and the observation group was treated with bevacizumab and erlotinib,the therapeutic effect was evaluated after 3 courses,at the same time,and the changes of level of serum CYFRA21-1 and KPS score were compared before and after treatment.The occurrence of side effects during the treatment was observed and recorded.Results After 3 courses of treatment,the total effective rate of the observation group was 82.50%,which was significantly higher than that of the control group 70.00%,and the difference was statistically significant(P<0.05).After 3 courses of treatment,the serum CYFRA21-1 level in the observation group was(2.45±1.02)μg/L,which was significantly lower than the pre-treatment(6.24±2.01)μg/L,and the serum CYFRA21-1 level in the control group was(3.37±1.13)μg/L,which was significantly lower than the pre-treatment(6.32±2.03)μg/L,and the observation group was lower than that in the control group,the differences were statistically significant(P<0.05).After 3 courses of treatment,the KPS score of the observation group was(79.46±10.26)points,which was significantly higher than the pre-treatment(60.46±10.17)points,and the KPS score of the control group was(72.31±10.19)points,which was significantly higher than the pre-treatment(60.71±10.20)points,and the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).The incidence of rash,diarrhea,and bleeding in the observation group were 42.50%,17.50%,and 10.00%,which were significantly lower than those of the control group,72.50%,40.00%,and 30.00%,the differences were statistically significant(P<0.05).Conclusion Bevacizumab combined with erlotinib is effective in the treatment of advanced NSCLC,which can significantly reduce the level of serum CYFRA21-1,reduce the occurrence of side effects,and improve the quality of life of patients with advanced NSCLC.It has certain clinical application value.